Intracerebral injection of AMPA causes axonal damage in vivo.
Brain injury following acute and chronic neurological conditions can involve both neuronal perikaryal and axonal damage, yet considerably less is known about the mechanisms of axonal damage. Oligodendrocytes and myelin are highly vulnerable to AMPA receptor-mediated excitotoxicity. In vitro studies using isolated white matter preparations have shown that AMPA receptor-mediated excitotoxicity results in axonal damage. The effect of AMPA on axons in vivo remains to be determined. We established an in vivo model to determine if axons were vulnerable to AMPA-mediated toxicity, and furthermore, to examine if axonal damage occurred through an AMPA receptor-mediated mechanism. Adult rats received stereotaxic injection of AMPA (2.5 or 25 nmol) or vehicle (PBS) into the external capsule. Axonal damage was detected in the external capsule and cortex in sections immunostained for cytoskeletal components microtubule associated protein-5 (MAP 5), the 200 kDa neurofilament subunit (NF 200) and non-phosphorylated neurofilament-H (SMI 32). Quantification of axonal damage in the external capsule of MAP 5-immunostained sections showed that AMPA caused a significant, dose-dependent increase in axonal damage compared to the vehicle-treated controls. AMPA also induced a dose-dependent increase in myelin and neuronal perikaryal damage. Systemic administration of the AMPA receptor antagonist SPD 502 significantly reduced the amount of AMPA-induced axonal, myelin and neuronal damage. These data suggest that AMPA induces structural damage to the cytoskeleton of axons in vivo, as well as neuronal and myelin damage, and that this occurs through AMPA receptor-mediated mechanisms. AMPA receptor antagonism may have therapeutic potential to salvage both axons and neuronal perikarya in a number of neurological disorders.
Division of Clinical Neuroscience, Wellcome Surgical Institute, University of Glasgow, Garscube Estate, Bearsden Road, Glasgow G61 1QH, UK. jill.fowler@ed.ac.uk
Jill H
JH
Fowler
Eileen
E
McCracken
Deborah
D
Dewar
James
J
McCulloch
D000818:Animals; D001369:Axons / Q000187:drug effects* / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000473:pathology; D003599:Cytoskeleton / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000008:administration & dosage / Q000633:toxicity*; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D008297:Male; D008869:Microtubule-Associated Proteins / Q000187:drug effects; D009186:Myelin Sheath / Q000187:drug effects / Q000473:pathology; D016900:Neurofilament Proteins / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors / Q000378:metabolism; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000008:administration & dosage / Q000633:toxicity*
D018690:Excitatory Amino Acid Agonists; D008869:Microtubule-Associated Proteins; D016900:Neurofilament Proteins; D018091:Receptors, AMPA; C051774:neurofilament protein H; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid